Marijuana strains that help you relax tend to be indica dominant and contain a balance of both THC and CBD. Strains containing a higher level of CBD than THC will allow you to relax your mind while preventing couch lock. If you’re looking for a more sedative relaxation experience, seek out indica-dominant strains with a higher amount of THC than CBD. Use our list of relaxing strains to explore which one will best meet your needs.

What are the requirements for a medical cannabis prescription?

If you think that medical cannabis may be able to help you manage your symptoms, the first step is assessing your eligibility for a prescription. Contact us at vape carts store Clinics for advice on your eligibility for medical cannabis oil in the UK.

There are many well known illnesses that medical cannabis may be used to help manage. If you have tried alternative methods for managing your pain or other difficulties with your illness and haven’t found any relief, it’s possible that pursuing a prescription for medical cannabis oil in the UK may be able to help.

Conditions that medical cannabis will help:

• Lower back pain
• Arthritic pain
• Fibromyalgia
• Neuropathic pain
• Pain associated with cancer
• Migraine or cluster headaches
• Anxiety, PTSD and depression
• Sleep Disorders
• Neurodevelopmental conditions

If you suffer from any of these conditions and have tried and failed when attempting at least two different medications to manage your condition, you may be eligible for a referral to vape carts store Clinics from your doctor. This way, we can support you with assessing if medical cannabis may provide some relief.

At least one third of the population in the UK is affected by chronic pain, and these issues are often either difficult to treat, or in some cases impossible with standard medication. The impact of chronic pain can affect the patient’s mental state just as harshly as their body, resulting in a slew of mental health conditions as well. While it is possible that medical cannabis could be helpful for those suffering with chronic pain, specialists understand that we still need to be very careful when it comes to prescribing this medication.

The reason the eligibility requirements for medical cannabis oil in the UK are so specific is because medical cannabis is classified as an unlicensed medicine in the UK. While it is completely legal if prescribed correctly, there are still some strict rules that must be followed to ensure that both patient and medical cannabis specialist are making the right choice with their treatment.

There are also two different naturally occurring cannabinoids (the active compound in medical cannabis that we use to manage your symptoms), and it’s important to make sure that patients are being prescribed the correct one to help manage their pain. Even if you have been referred to a medical cannabis specialist, it still doesn’t necessarily mean that they will determine that it will be the best form of management for your condition.

The legislation of medical cannabis oil in the UK allows only specialist doctors that must be registered on the General Medical Council Specialist Register to prescribe these medicines. vape carts store Clinics is one such registered organisation and this is why we are able to offer prescription services to patients. At this point, eligibility is still on a case-by-case basis as medical cannabis might work wonders in helping some patients manage their pain, but for others it might do very little.

So in summary, if you are suffering from a medication condition that has not been helped with prior medications, it may be in your best interest to speak with your doctor about getting a referral to a team of medically cannabis specialists such as those at vape carts store Clinics. We can take the time to assess if medical cannabis oil available in the UK would be the best way to help manage your pain and take you through the whole treatment process to make sure you are safe and healthy.

Cannabis-based products for medicinal use

The National Institute for Health and Care Excellence (NICE) has published Technology Appraisals for the use of cannabidiol  for severe treatment-resistant epilepsies.

• Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
• Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
• Cannabidiol for treating seizures caused by tuberous sclerosis complex

NICE has also published a guideline on cannabis-based products for medicinal use.

The guideline and technology appraisals include recommendations for people with:

• chronic pain
• intractable nausea and vomiting
• spasticity
• severe treatment-resistant epilepsy.

Guidance and advice produced previously by Professional Organisations has now been superseded by issuing of the NICE guidance as outlined above.

However, the British Paediatric Neurology Association (BPNA) has guidance on the use of cannabis-based products for medical use in paediatric patients with certain forms of severe epilepsy. It recommends that CBD (Epidiolex^®) should be the default choice when considering prescription of a cannabis-derived medical product in its licensed indications. It does not recommend prescribing other non-licensed cannabis-derived medical products, which includes all artisanal cannabis oils, whether or not they comply with good manufacturing practice (GMP) or good distribution practice (GDP) standards.

The only robust evidence for efficacy and safety in childhood epilepsies relates to use of pure cannabidiol (Epidyolex^®). Currently there is no good evidence that products that contain THC are either safe or efficacious and there is a concern about the harmful effects of THC on the developing brain. There is evidence that chronic high exposure to THC during recreational cannabis use can affect brain development, structure, and mental health. Therefore, further evidence is required before these products can be routinely commissioned or prescribed.

Cannabis has many active chemical constituents and two of these constituents, tetrahydrocannabinol (THC) and cannabidiol (CBD) have been investigated the most in respect of their medical value. THC is the major psychoactive constituent of cannabis and is considered responsible for giving so called “highs” to users of cannabis. CBD on the other hand, is not psychoactive.

‘Pure CBD’ is not a controlled drug for the purposes of the 1971 Misuse of Drugs Act.

Products falling within Schedule 2 will contain varying quantities and ratios of THC and CBD and may be available in a range of pharmaceutical forms. These products are unlicensed, and the quality of these products has not been assessed by the regulator.